Anti-PD-1 Therapy in Combination With Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Trial ID # NCT03029598
Phase I/II
Drug Class Immunotherapy: Checkpoint Inhibitors/PD-1
Drug Name Pembrolizumab
Alternate Drug Names Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475
Drugs in Trial Carboplatin, Pembrolizumab
Eligible Participant

Platinum resistant ovarian cancer

Patients Enrolled

27; median 5 prior therapies (2-9)

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, DCR, PFS, OS, evaluated per RECIST


Exploratory: PD-L1 status


ORR: 13% (3PR, n=23)
DCR: 78.2% (3PR, 15SD, n=23)
PFS: 4.6 months
OS: 12.83 months

7 of 23 evaluable patients (30.4%) had archival tumor with modified percent scoring ≥5 for PD-L1 and all achieved PR (3/7, 42.8%) or SD(4/7, 57.2%)

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE:


Promising activity of pembrolizumab with low dose carboplatin in heavily pretreated patients


Liao JB et al. Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer - interim results. J Clin Oncol (2019) 37 (suppl; abstr 5519)